This step involves dividing breast cancer cases into specific subtypes like hormone receptor-positive, HER2-positive, or triple-negative breast cancer, which are known to have varying responses to treatments and differing prognoses. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.